Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00357
|
|||||
| Drug Name |
Vibegron
|
|||||
| Synonyms |
Beova; Beova (TN); VIBEGRON; Vibegron (JAN/USAN); Vibegron [USAN:INN]; compound 7 [PMID: 26709102]; vibegronum
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Overactive bladder disorder [ICD11: GC50.0] | phase 3 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H28N4O3
|
|||||
| Canonical SMILES |
C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O
|
|||||
| InChI |
InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
|
|||||
| InChIKey |
DJXRIQMCROIRCZ-XOEOCAAJSA-N
|
|||||
| CAS Number |
CAS 1190389-15-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 444.5 | Topological Polar Surface Area | 94 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.8
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:142418
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT03902080) Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.